Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03463876
Recruitment Status : Active, not recruiting
First Posted : March 13, 2018
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: SHR 1210+apatinib Phase 2

Detailed Description:

SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI).

Patients with advanced HCC who failed or intolerable to sorafenib will received apatinib 250mg orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 190 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Single-arm, Open-labeled Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC
Actual Study Start Date : February 5, 2018
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : December 30, 2019

Arm Intervention/treatment
Experimental: SHR-1210+Apatinib
Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
Drug: SHR 1210+apatinib
SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Up to approximately 12 months ]
    Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).


Secondary Outcome Measures :
  1. Duration of Response (DoR) [ Time Frame: Up to approximately 12 months ]
    Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

  2. Disease Control Rate (DCR) [ Time Frame: Up to approximately 12 months ]
    Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

  3. Time to objective response(TTR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). [ Time Frame: Up to approximately 12 months ]
    Time to objective response,TTR

  4. 9-month survival rate [ Time Frame: Up to approximately 12 months ]
    9-month survival rate

  5. 12-month survival rate [ Time Frame: Up to approximately 12 months ]
    12-month survival rate

  6. Overall survival(OS) [ Time Frame: Up to approximately 18 months ]
    Overall survival(OS)

  7. Progression-free survival(PFS) [ Time Frame: Up to approximately 12 months ]
    Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

  8. Safety as measured by the rate of AEs, SAEs and laboratory abnormalities [ Time Frame: From the first assignment of informed consent form up to 90 days after the last dose ]
    Safety as measured by the rate of AEs, SAEs and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 )



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18 years old, both genders.
  2. Conform to the clinical diagnosis standard strictly or histological or cytological confirmation of HCC(hepatocellular carcinoma) and with at least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.1.
  3. Liver function status Child-Pugh Class A.
  4. Barcelona Clinic Liver Cancer stage Category B or C.
  5. Failure or intolerance to prior treatment with targeted therapy.
  6. Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  7. Life expectancy of at least 12 weeks.
  8. Adequate bone marrow, liver and renal function (without blood transfusion, without growth factor or blood components support within 14 days before enrollment).

Exclusion Criteria:

  1. Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded.
  2. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration.
  3. More than one regimen.
  4. Known history of hypersensitivity to any components of the SHR-1210 formulation, or other antibody formulation.
  5. Known or occurrence of central nervous system (CNS) metastases or hepatic encephalopathy.
  6. Patients with tumor burden ≥50% of the liver volume or received liver transplantation.
  7. Patients with clinical symptoms of ascites.
  8. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg.
  9. Clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure (New York heart association (NYHA) class > 2), ventricular arrhythmia which need medical intervention.
  10. Coagulation abnormalities (INR>2.0、PT>16s), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy.
  11. Previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency, such as: esophageal varices, local active ulcerative lesions, gastric ulcer and duodenal ulcer, the ulcerous colitis, gastrointestinal diseases such as portal hypertension or resection of tumor with bleeding risk, etc.
  12. Previous Arterial/venous thrombosis events within 3 months.
  13. Proteinuria ≥ (++) and 24 hours total urine protein > 1.0 g.
  14. Prior systemic chemotherapy, radiotherapy, immunotherapy, hormone therapy, surgery or target therapy within 4 weeks (Or 5 half-life of the drug, calculate the longer ) before the study drug administration, or any unresolved AEs > Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.
  15. Active infection or an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing.
  16. History of immunodeficiency or human immunodeficiency virus (HIV) infection.
  17. HBV DNA>2000 IU/ml(or 104copies/ml),HCV RNA>103copies/ml,HBsAg+ and anti-HCV+;
  18. Patients with other malignant tumor (except cured skin basal cell carcinoma and cervical carcinoma).
  19. Patients who has bone metastasis, has received Palliative radiotherapy (radiotherapy area > 5% marrow area).
  20. Patients must not have had prior treatment with SHR-1210 or any other PD-L1 or PD-1 antagonists or apatinib.
  21. Patients who may receive live vaccine during the study, or previous had vaccination within 4 weeks.
  22. Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study or would interfere with the interpretation of the results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03463876


Locations
Layout table for location information
China, Beijing
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Beijing, Beijing, China, 100071
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Layout table for additonal information
Responsible Party: Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier: NCT03463876    
Other Study ID Numbers: SHR-1210-APTN-Ⅱ-208-HCC
First Posted: March 13, 2018    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Apatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action